As Pfizer offloads its generic Upjohn unit in a merger with Mylan, the drugmaker will lean on its blockbuster stalwarts as it moves into the next phase. One of those longtime top-sellers, pneumonia vaccine Prevnar 13, could be in for an even brighter future with years of market exclusivity ahead.
Prevnar hit $5.95 billion in sales in 2019, making it Pfizer's best-selling solo medicine—unlike blood thinner Eliquis, which is co-marketed with Bristol Myers Squibb. In 2026, the year Prevnar loses patent protection, Evaluate Pharma forecasts the shot will rake in $7.06 billion in sales.
With Prevnar's generic due date on the horizon, Pfizer is aggressively chasing an approval for a Prevnar follow-up. In the meantime, the drugmaker is hoping to lean on its older vaccine to get it over the hump of a possible generics unit spinoff.